BibTex format
@article{Corbaux:2026:10.1016/j.ijgc.2026.104805,
author = {Corbaux, P and You, B and McNeish, I and Welch, S and Tinker, AV and Mirza, MR and Lindemann, K and Kagimura, T and Ray-Coquard, IL and Subtil, F and Péron, J and Carty, K and Kelly, C and Colomban, O and Karamouza, E and Cook, A and Paoletti, X and Glasspool, RM and Yanaihara, N},
doi = {10.1016/j.ijgc.2026.104805},
journal = {International Journal of Gynecological Cancer},
title = {Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis},
url = {http://dx.doi.org/10.1016/j.ijgc.2026.104805},
volume = {36},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Objective: Growing evidence suggests potential ethnic and geographical variations in chemotherapy efficacy. The CA125 ELIMination rate constant K score is a pragmatic and reproducible indicator of tumor chemosensitivity in newly diagnosed ovarian cancer. We compared ELIMination rate constant K distributions and prognostic performances between patients enrolled in Japanese and Western trials who had stage III/IV serous ovarian cancer from the Gynecologic Cancer InterGroup individual-patient-data Meta-Analysis in OVarian cancer. Methods: The ELIMination rate constant K values were previously estimated for 5884 women receiving first-line chemotherapy for ovarian cancer. Data from 246 women enrolled in the Japanese JGOG-3016 trial were compared to 2561 patients from Western trials. ELIMination rate constant K was analyzed as a binary variable (favorable ≥1.0 vs unfavorable <1.0). Prognostic value for progression-free survival and overall survival was assessed using univariable and multi-variable models. A standardization cut-off specific to patients enrolled in the Japanese trial was explored using maximally selected rank statistics. Results: KELIM was significantly higher in patients enrolled in the Japanese trial (median 0.071 day<sup>-1</sup> vs 0.056 day<sup>-1</sup>; p <.0001). Using the standard cut-off, favorable ELIMination rate constant K was independently associated with improved progression-free survival (hazard ratio 0.59, 95% confidence interval 0.43 to 0.83) and overall survival (hazard ratio 0.53, 95% confidence interval 0.36 to 0.79) in patients from the Japanese trial. Applying the exploratory cut-off of 0.07 day<sup>-1</sup> strengthened prognostic discrimination (progression-free survival: hazard ratio 0.35, 95% confidence interval 0.25 to 0.49, p <.0001; overall survival: hazard ratio 0.40, 95% confidence interval 0.26 to 0.61, p <.0001). Conclusions: Potential higher ELIMination rate constant K-asse
AU - Corbaux,P
AU - You,B
AU - McNeish,I
AU - Welch,S
AU - Tinker,AV
AU - Mirza,MR
AU - Lindemann,K
AU - Kagimura,T
AU - Ray-Coquard,IL
AU - Subtil,F
AU - Péron,J
AU - Carty,K
AU - Kelly,C
AU - Colomban,O
AU - Karamouza,E
AU - Cook,A
AU - Paoletti,X
AU - Glasspool,RM
AU - Yanaihara,N
DO - 10.1016/j.ijgc.2026.104805
PY - 2026///
SN - 1048-891X
TI - Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis
T2 - International Journal of Gynecological Cancer
UR - http://dx.doi.org/10.1016/j.ijgc.2026.104805
VL - 36
ER -